Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa

Chemotherapy

Volumn 55, Issue 6, 2009, Pages 446-450

  Ozbek, Berna ^a   Otuk, Gulten ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cefepime; Levofloxacin; Post antibiotic effect; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

CEFEPIME; LEVOFLOXACIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; CULTURE MEDIUM; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; TIME FACTORS; TOBRAMYCIN;

EID: 71249095647     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000265128     Document Type: Article

References (35)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
2. Caatay AA, Ozcan PE, Gulec L, Ince N, Tugrul S, Ozsut H, Cakar N, Esen F, Eraksoy H, Calangu S: Risk factors for mortality of nosocomial bacteraemia in intensive care units. Med Princ Pract 2007; 16: 187-192.
3. Osmon S, Ward S, Fraser VJ, Kollef MH: Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa . Chest 2004; 125: 607-616.
4. Safdar N, Handelsman J, Maki D: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-527.
5. Bodey GP, Jadeja L, Elting L: Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145: 1621-1629.
6. Burgess DS, Hall RG, Hardin TC: In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003; 46: 131-137.
7. Hamidah A, Lim YS, Zulkifli SZ, Zarina AL, Nordiah AJ, Jamal R: Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J 2007; 48: 615-619.
8. Craig WA, Gudmundsson S: The postantibiotic effect; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams and Wilkins, 1996, pp 296-329.
9. Bundtzen RW, Gerber AU, Cohn DL, Craig WA: Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 28-37.
10. McDonald PJ, Craig WA, Kunin CM: Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 1977; 135: 217-223.
11. Burgess DS: Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115(suppl 3):19-23.
12. Gilbert DN: Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399-405.
13. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P: Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-339.
14. Smith SV, Gould IM: Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance. Expert Rev Anti Infect Ther 2004; 2: 227-234.
15. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE: Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52: 668-674.
16. Spivey JM: The postantibiotic effect. Clin Pharm 1992; 11: 865-875.
17. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA: Experience with a oncedaily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28: 936-942.
18. Drusano GL, Johnson DE, Rosen M, Standiford HC: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-490.
19. Rea RS, Capitano B: Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 2007; 28: 596-603.
20. Rodvold KA, Neuhauser M: Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21: 233-252.
21. Clinical and Laboratory Standards Institute (CLSI) 2006: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, ed 7. Approved Standard M7-A7. Wayne, CLSI, 2006.
22. Pillai SK, Moellering RC Jr, Eliopoulos GM: Antimicrobial combinations; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 5. Philadelphia, Lippincott Williams and Wilkins, 2005, pp 365-440.
23. Odds FC: Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
24. National Committee for Clinical Laboratory Standards (NCCLS) 1999: Methods for Determining a Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. Wayne, NCCLS, 1999.
25. Gudmundsson S, Einarsson S, Erlendsdottir H, Moffat J, Bayer W, Craig WA: The postantibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J Antimicrob Chemother 1993; 31(suppl D):177-191.
26. Zhu ZY, Li RC: Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model. J Antimicrob Chemother 1998; 42: 61-65.
27. Ali MZ, Goetz MB: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809.
28. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 24: 717-725.
29. Houston AK, Jones RN: Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. Diagn Microbiol Infect Dis 1994; 18: 57-59.
30. Carbon C: Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 2001; 47(suppl 3):9-14.
31. Gerceker AA, Otuk G: Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa . Chemotherapy 1995; 41: 433-436.
32. Gould IM, Jason AC, Milne K: Use of the Malthus Microbial Growth Analyser to study the post antibiotic effect of antibiotics. J Antimicrob Chemother 1989; 24: 523-531.
33. Rolinson GN, Macdonald AC, Wilson DA: Bactericidal action of beta-lactam antibiotics on Escherichia coli with particular reference to ampicillin and amoxycillin. J Antimicrob Chemother 1977; 3: 541-553.
34. Liao X, Hancock RE: Susceptibility to betalactam antibiotics of Pseudomonas aeruginosa overproducing penicillin-binding protein 3. Antimicrob Agents Chemother 1997; 41: 1158-1161.
35. Maejima T, Inoue M, Mitsuhashi S: In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother 1991; 35: 104-110.